Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

Summary

This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX improves treatment, compared to standard of care (SOC), which is no further treatment.

Timeline

Start

2015-03-26

Primary completion

2017-09-21

Completion

2017-09-21

Outcome

Outcome not reported

Stopped (Enrollment): “insufficient accrual”

Drugs

Indications